[go: up one dir, main page]

KR910011817A - 중추 신경계 약제로서 유용한 치환 시클로헥센 - Google Patents

중추 신경계 약제로서 유용한 치환 시클로헥센 Download PDF

Info

Publication number
KR910011817A
KR910011817A KR1019900019932A KR900019932A KR910011817A KR 910011817 A KR910011817 A KR 910011817A KR 1019900019932 A KR1019900019932 A KR 1019900019932A KR 900019932 A KR900019932 A KR 900019932A KR 910011817 A KR910011817 A KR 910011817A
Authority
KR
South Korea
Prior art keywords
pyridinyl
substituted
cyclohexen
unsubstituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900019932A
Other languages
English (en)
Other versions
KR0166359B1 (ko
Inventor
윌리암 카프레이드 브래들리
카를로스 쟝 주안
제인 스미스 사라
데이비드 와이즈 로렌스
Original Assignee
로널드 에이. 다이놀트
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로널드 에이. 다이놀트, 워너-램버트 캄파니 filed Critical 로널드 에이. 다이놀트
Publication of KR910011817A publication Critical patent/KR910011817A/ko
Application granted granted Critical
Publication of KR0166359B1 publication Critical patent/KR0166359B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measurement Of Radiation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

중추 신경계 약제로서 유용한 치환 시클로헥센
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(I)의 화합물 및 대응하는 그의 광학이 성질체 또는 제약학적으로 허용되는 산 부가염.
    식중 R1은 아릴, 치환되지않거나 또는 저급 알킬, 저급 알콕시 또는 할로겐으로 치환된 2,3 또는 4-피리디닐, 치환되지 않거나 또는 저급알킬, 저급알콕시 또는 할로겐으로 치환된 2,4 또는 5-피리미디닐, 치환되지 않거나 또는 저급 알킬, 저급 알콕시 또는 할로겐으로 치환된 2-피라지닐, 치환되지않거나 또는 저급 알킬, 또는 할로겐으로, 치환된 2 또는 3-티에닐, 치환되지않거나 또는 저급 알킬 또는 할로겐으로 치환된 2 또는 3-푸라닐, 치환되지않거나 또는 저급 알킬 또는 할로겐으로 치환된 2,4 또는 5-티아졸릴이고, m은 0 또는 1 내지 2사이의 정수이고, R2는
    (여기서, R1은 상기에서 정의한 바와 같음)n은 0또는 1 내지 4사이의 정수이다.
  2. 제1항에 있어서, R1이 치환되지 않거나 또는 파라-저급알킬, 파라-저급 알콕시, 파라-저급티오알콕시 또는 파라-할로겐으로 치환된 페닐, 2,3 또는 4-피리디닐, 2 또는 3-푸라닐, 2 또는 3-티에닐, 또는 2,4 또는 5-티아졸릴이고, m이 0이고 0 또는 1 내지 3사이의 정수이며 R2가
    (여기서, R1은 상기에서 정의한 바와 같음)인 화합물.
  3. 제2항에 있어서, R1이 치환되지 않거나 또는 파라-저급 알콕시 또는 파라-할로겐으로 치환된 페닐, 2,3 또는 4-피리디닐, 2 또는 3-티에닐, 또는 2,4 또는 5-티아졸릴이고, m이 0이고 n이 0 또는 1 내지 2사이의 정수이며 R2가
    (여기서, R1은 상기에서 정의한 바와 같음)인 화합물.
  4. 제3항에 있어서, 다음군중에서 선택되는 화합물 : (±)-(2-피리디닐)-4-[4-(2-피리디닐)-3-시클로헥센-1-일]피페라진, (±)-(2-피리디닐)-4-[4-(3-피리디닐)-3-시클로헥센-1-일]피페라진, (±)-(2-피리디닐)-4-[4-(2-티에닐)-3-시클로헥센-1-일]피페라진, (±)-1-(2-피리디닐)-4-[4-(3-티에닐)-3-시클로헥센-1-일]피페라진, (±)-1-(4-페닐-3-시클로헥센-1-일)-4-(2-피리디닐)피페라진, (±)-1-(2-피리디닐)-4-[[4-(2-티에닐)-3-시클로헥센-1-일]메틸]피페라진, (±)-1-(2-피리디닐)-4-[[4-(2-피리디닐)-3-시클로헥센-1-일]메틸]피페라진, (±)-1-(2-피리디닐)-4-[[4-3-시클로헥센 -1-일]메틸]피페라진, (±)-1-(2-피리디닐)-4-[2-[4-(2-티에닐)-3-시클로헥센-1-일]메틸]피페라진, (±)-1-[2-(4-페닐-3-시클로헥센-1-일]에틸]-4-(2-피리디닐)피페라진, (±)-1-(2-피리디닐)-4-[2-[4-(2-피리디닐)-3-시클로헥센-1-일]에틸]피페라진, (±)-1-[2-[4-(4-플루오로페닐)-3-시클로헥센-1-일]에틸]-4-(2-피리디닐)피페라진, (±)-1-(2-피리디닐)-4-[2-[4-(2-티아졸릴)-3-시클로헥센-1-일]에틸]피페라진, (±)-1,2,3,6-테트라히드로-4-페닐-1-[2-[4-(2-티에닐)-3-시클로헥센-1-일]에틸]피리딘, (±)-2-[4-(3,6-디히드로-4-페닐-1(2H)-피리디닐)-1-시클로헥센-1-일]피리딘.
  5. 정신질환, 우울증, 고혈압증, 유루증, 무월경, 월경장애, 성기능이상, 파킨스증후근 또는 헌팅톤 무도병을 앓는 환자에게 치료상 유효량의 제1항의 화합물을 단위 투여형으로 투여하는 것으로 이루어진 상기 질환의 치료방법.
  6. 정신 분열증을 앓는 환자에게 치료상 유효량의 제1항의 화합물을 단위 투여형으로 투여하는 것으로 이루어진 정신 분열증의 치료 방법.
  7. 우울증을 앓는 환자에게 치료상 유효량의 제1항의 화합물을 단위 투여형으로 투여하는 것으로 이루어진 우울증의 치료 방법.
  8. 치료상 유효량의 제1항의 화합물을 제약학적으로 허용되는 부형제, 희석제 도는 담체와 혼합하여 이루어진, 도파민 작용제, 항정신질환제, 고혈압 강하제 또는 항우울증제로서 투여하기 위한 제약 조성물.
  9. 하기 일반식(Ⅱ)의 화합물을 탈수제에 의해 탈수시켜 일반식(I)의 화합물을 제조하고, 필요한 경우 일반식(I)의 화합물을 통상의 방법에 의해 제약학적으로 허용되는 대응하는 산 부가염으로 전환시키고, 또한 필요한 경우, 제약학적으로 허용되는 산 부가염을 통상의 방법에 의해 일반식(I)의 화합물로 전환시키는 것으로 이루어진 일반식(I)의 화합물 및 대응하는 그의 광학이성질체 또는 제약학적으로 허용되는 산부가염의 제조방법.
    식중 R1은 아릴, 치환되지않거나 또는 저급 알킬, 저급 알콕시 또는 할로겐으로 치환된 2,3 또는 4-피리디닐, 치환되지 않거나 또는 저급알킬, 저급알콕시 또는 할로겐으로 치환된 2,4 또는 5-피리미디닐, 치환되지 않거나 또는 저급 알킬, 저급 알콕시 또는 할로겐으로 치환된 2-피라지닐, 치환되지않거나 또는 저급 알킬, 또는 할로겐으로 치환된 2 또는 3-티에닐, 치환되지않거나 또는 저급 알킬 또는 할로겐으로 치환된 2 또는 3-푸라닐, 치환되지않거나 또는 저급 알킬 또는 할로겐으로 치환된 2,4 또는 5-티아졸릴이고, m은 0 또는 1 내지 2사이의 정수이고, n은 0또는 1 내지 4사이의 정수이고, R2는
    (여기서, R1은 상기에서 정의한 바와 같음)이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900019932A 1989-12-06 1990-12-05 중추 신경계 약제로서 유용한 치환 시클로헥센 Expired - Fee Related KR0166359B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/446,950 US4975445A (en) 1989-12-06 1989-12-06 Substituted cyclohexenes as central nervous system agents
US446,950 1989-12-06

Publications (2)

Publication Number Publication Date
KR910011817A true KR910011817A (ko) 1991-08-07
KR0166359B1 KR0166359B1 (ko) 1999-01-15

Family

ID=23774425

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900019932A Expired - Fee Related KR0166359B1 (ko) 1989-12-06 1990-12-05 중추 신경계 약제로서 유용한 치환 시클로헥센

Country Status (18)

Country Link
US (1) US4975445A (ko)
EP (1) EP0431579B1 (ko)
JP (1) JP3044790B2 (ko)
KR (1) KR0166359B1 (ko)
AT (1) ATE109136T1 (ko)
AU (1) AU630770B2 (ko)
CA (1) CA2031570C (ko)
DE (1) DE69011054T2 (ko)
DK (1) DK0431579T3 (ko)
ES (1) ES2057341T3 (ko)
FI (1) FI100240B (ko)
IE (1) IE66117B1 (ko)
MY (1) MY107354A (ko)
NO (1) NO176097C (ko)
NZ (1) NZ236336A (ko)
PH (1) PH27326A (ko)
PT (1) PT96084B (ko)
ZA (1) ZA909774B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314896A (en) * 1991-11-20 1994-05-24 Warner-Lambert Company 1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents
ZA929008B (en) * 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
CN1047594C (zh) * 1993-01-02 1999-12-22 布里斯托尔-迈尔斯斯奎布公司 哌嗪基或哌啶基环己醇、其制法和用途
GB9300194D0 (en) * 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5391570A (en) * 1993-10-14 1995-02-21 Bristol-Myers Squibb Aminomethyl-benzodioxane and benzopyran serotonergic agents
US6200994B1 (en) 1999-01-07 2001-03-13 American Home Products Corp 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
CA2355361A1 (en) * 1999-01-07 2000-07-13 Richard Eric Mewshaw New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
CN1342074A (zh) 1999-01-28 2002-03-27 布里斯托尔-迈尔斯斯奎布公司 抗抑郁的杂环化合物
US7964605B2 (en) * 2008-05-29 2011-06-21 Sk Holdings Co., Ltd. Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof
US7985752B2 (en) * 2008-05-29 2011-07-26 Sk Holdings Co., Ltd. Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1327691A (en) * 1970-08-31 1973-08-22 Upjohn Co Phenyl cyclohexenylamines and the preparation thereof
GB1311580A (en) * 1970-08-31 1973-03-28 Upjohn Co 4-substituted phenyl cyclohexylamines and the preparation thereof
GR73633B (ko) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5102889B1 (en) * 1990-09-27 1993-05-11 2-(4-piperidinyl)-1h-pyrido(4,3-b)indol-1-ones and related compounds

Also Published As

Publication number Publication date
EP0431579B1 (en) 1994-07-27
CA2031570C (en) 2001-09-11
AU630770B2 (en) 1992-11-05
FI100240B (fi) 1997-10-31
DK0431579T3 (da) 1994-10-31
IE904385A1 (en) 1991-06-19
JP3044790B2 (ja) 2000-05-22
PT96084B (pt) 1998-02-27
FI905957A7 (fi) 1991-06-07
DE69011054D1 (de) 1994-09-01
FI905957A0 (fi) 1990-12-03
NZ236336A (en) 1992-04-28
DE69011054T2 (de) 1994-12-08
NO905254D0 (no) 1990-12-05
NO905254L (no) 1991-06-07
NO176097C (no) 1995-02-01
PT96084A (pt) 1991-09-30
ZA909774B (en) 1992-08-26
PH27326A (en) 1993-06-08
CA2031570A1 (en) 1991-06-07
ES2057341T3 (es) 1994-10-16
EP0431579A3 (en) 1991-12-11
NO176097B (no) 1994-10-24
JPH03251576A (ja) 1991-11-11
US4975445A (en) 1990-12-04
AU6770190A (en) 1991-06-13
EP0431579A2 (en) 1991-06-12
IE66117B1 (en) 1995-12-13
KR0166359B1 (ko) 1999-01-15
MY107354A (en) 1995-11-30
ATE109136T1 (de) 1994-08-15

Similar Documents

Publication Publication Date Title
KR970707101A (ko) 치환된 벤질아민 유도체; 신규한 부류의 신경펩타이드 y1 특이적 리간드(certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands)
KR910011817A (ko) 중추 신경계 약제로서 유용한 치환 시클로헥센
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
EA199800909A1 (ru) Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
KR910000708A (ko) 1-인돌릴알킬-4-(치환- 피리디닐) 피페라진류
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
CN100451016C (zh) 作为5-羟色胺5ht-2受体的激动剂或拮抗剂的哌嗪基嘧啶化合物
KR850006402A (ko) 항정신병의 1-플루오로페닐부틸-4-(2-피리미디닐) 피페라진 유도체
KR920014472A (ko) {ω-[4-(2-피리미디닐)-1-피페라지닐]알킬}-1H-아졸 유도체의 인식기능 장해 치료를 위한 의약품 제조에의 이용
EA199800912A1 (ru) Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства
KR920000754A (ko) 환식아미드 유도체
KR940005609A (ko) 벤즈이미다졸의 피페리딘 유도체
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
KR830007630A (ko) 아민유도체의 제조방법
JPH10203986A (ja) 眼疾患用薬剤
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
KR890008094A (ko) 4-페닐-4-[n-(페닐)아미도]피페리딘 유도체, 제약학적 조성물 및 이런 화합물을 이용하는 방법
KR900001720A (ko) 항고혈압제로서의 에테르성 n-말단 아미노디올 아미노산 유도체
KR960702456A (ko) 4-(p-플로오로페닐)-3-[(3,4-(메틸렌디옥시)페녹시)메틸]피페리딘의 n-p-할로벤조일메틸 유도체(n-p-halobenzoylmethyl derivatives of 4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]piperidine)
ATE183743T1 (de) Thiazolidine-dion-derivate als antihyperglykemische mittel
KR880007491A (ko) Paf-길항물질인피페라진화합물
KR870006027A (ko) 치환 피페라진-1,4-나프탈렌디온과 그 산부가염 및 그들의 제조방법
KR890002079A (ko) 1-[2-(페닐메틸)페닐]피페라진 및 그의 제조방법
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20030718

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040924

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040924

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000